It’s a sign that’s impossible to ignore. As you soon as you pull up the Price Overview for Recursion Pharmaceuticals (RXRX), you’re greeted with a clear message: Barchart’s Technical Opinion indicator rates RXRX stock as a 72% Strong Sell. From an empirical perspective, suggesting a contrarian position would place you on shaky ground. Since the start of the year, RXRX stock is down nearly 28%, which in many respects is understandable given the uncertainties associated with the broader healthcare ecosystem ...